Knowledge of the pathophysiology of articular carti lage is crucial in understanding the mechanisms under lying joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). In a previous issue of Arthritis Research and Th erapy, Berg and colleagues [1] have provided new insights in this fi eld by showing for the fi rst time that chondrocytes express chemerin and its cognate receptor, ChemR23, and that this system may be involved in cartilage degradation.
Chemerin is a secreted protein that exerts its functions by binding the G protein-coupled receptor ChemR23. It was fi rst discovered as a chemotactic peptide directing macrophages and dendritic cells expressing ChemR23 toward sites of infl ammation, being involved in both adaptive and innate immunity [2] . As often happens, regulatory proteins have pleiotropic functions. ChemR23 is also expressed by endothelial cells, where it is up-regulated by pro-infl ammatory cytokines, and chemerin strongly induces angiogenesis in vitro by promoting endothelial cell proliferation and remodeling through stimulation of matrix metalloproteinase (MMP) activity [3] . Interest in chemerin has grown since it was discovered in fat tissue as a novel adipokine secreted by adipocytes, which also express ChemR23. Chemerin is up-regulated in white fat cells upon IL-1β stimulation in vitro and chemerin serum levels are increased in obese patients; thus, chemerin may be the functional link between chronic infl ammation and obesity, and obesityrelated disorders such as type 2 diabetes and cardiovascular diseases [4] .
Th ere is evidence that chemokines may play an important role in recruiting infl ammatory cells into the joints and contribute to chronic synovitis in OA and RA [5] . Additionally, chemokines exert catabolic eff ects on cartilage. Functional chemokine receptors (CCR-1, CCR-2, CCR-3, CCR-5, CXCR-1, and CXCR-2) are detectable on human articular chondrocytes and up-regulated in OA cartilage. Th e interactions of these receptors with their ligands activate matrix degradation by inducing MMP-3 synthesis [6] . In their study, Berg and colleagues [1] explored whether chondrocytes also express ChemR23 and investigated the metabolic eff ects of chemerin stimulation on chondrocytes. A series of experiments was performed on human native cartilage or cultured chondrocytes isolated from joints of patients undergoing knee arthroplasty for severe OA, and patients subjected to autologous chondrocyte transplantation. Cartilage from young subjects undergoing reconstruction of anterior cruciate ligament was taken as normal control. ChemR23 and prochemerin transcripts were detected in chondrocyte cultures by reverse transcriptase PCR. Furthermore, ChemR23 and chemerin proteins were detected in chondrocytes in vitro by immunocyto chemis try. Th ese fi ndings were confi rmed by immunohistochemistry in cartilage biopsies, in which resident chondrocytes showed positive staining for both ChemR23 and chemerin. Th e eff ects of challenging isolated chondrocytes with recombinant chemerin in vitro were also investigated. Chemerin binding to ChemR23 led to
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Chemerin is a chemokine that, through the engagement of its counter-receptor, ChemR23, attracts pro-infl ammatory cells. However, chemerin has been shown to play other functions and a recent study by Berg and colleagues demonstrates that chemerin/ ChemR23 is a system beyond chemokines. Human articular chondrocytes produce chemerin and express ChemR23, and upon stimulation with recombinant chemerin increase the production of pro-catabolic cytokines and metalloproteinases. The latter are up-regulated in osteoarthritic cartilage and cause extracellular matrix breakdown. Since an increase of chemerin in fat tissue and serum of obese patients has been reported, this new feature of chemerin may represent a functional link between obesity and osteoarthritis. MAPKs but not of Akt. Th is suggests that intracellular downstream events upon chemerin stimulation occur through the Akt/MEK/MAPK pathway. Th e most outstanding fi nding of this study was the demonstration that chemerin regulates the production of pro-infl ammatory cytokines and MMPs by human chondrocytes in vitro. IL-1β, TNF-α, IL-6, and IL-8 as well as MMP-13 and others MMPs were signifi cantly increased in the supernatants of chondrocyte cultures stimulated with recombi nant chemerin. It is noteworthy that OA chondrocytes secreted larger amounts of cytokines than chondrocytes from healthy subjects. MMPs play a key role in the remodeling of cartilage matrix and their increase is crucial in the induction of cartilage damage in OA and RA. In OA, MMP-13 has been shown to be the most important collagenase and, together with ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin motifs-5), causes the breakdown of the collagen and aggre can framework of the extracellular matrix and initiates the destruction of cartilage [7] . Consistent with this study, chemerin production by chondrocytes has also been reported by Conde and colleagues [8] . Th ey have shown that chondrocytes synthesize chemerin and its expression is increased by IL-1β stimulation. Furthermore, dexametasone increased the eff ect of IL-1β on mRNA expression of chemerin by chondrocytes suggesting that intra-articular injections of steroids as treatment of OA may damage the articular cartilage.
All together, these data strongly suggest that the chemerin/ChemR23 system is involved in cartilage damage in OA, and further studies will unravel its specifi c role. However, chemerin might not be one of the many redundant mediators that activate chondrocyte catabolic pathways, but may be a crucial link between obesity and OA. For years obesity has been regarded as a risk factor for developing OA in weight-bearing joints, but a growing body of evidence is showing that obesity is a mild infl ammatory disease and that a pro-infl ammatory network links fat tissue to obesity-related disease, including OA [9] . Chemerin is produced by adipocytes as well as chondrocytes and is up-regulated in both obesity and OA, and might be a promising fi eld of research to better understand and treat these two functionally associated diseases.
Abbreviations IL, interleukin; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; OA, osteoarthritis; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
